Constrictive Pericarditis and Bilateral Pleural Effusions Unmasked in an HLA-B27 Positive Patient Authors: Michael Villalonga, Astefanos Al-Dalakta, Joseph El Roumi, Muhammad Ehsan, Abdel Hadi El Hajjar, Chadi Tabaja, Allan L. Klein Published: 2026 ABSTRACT BackgroundConstrictive pericarditis (CP) is most often idiopathic, postviral, postoperative, or autoimmune in etiology. HLA-B27 is strongly associated with spondyloarthropathies, which may have cardiac manifestations including conduction system abnormalities and aortopathy; however, an association with CP is not well described.Case SummaryA 40-year-old previously healthy man presented with progressive dyspnea, fevers, and cough. Initial imaging demonstrated acute pericarditis with subsequent progression to constrictive physiology. Extensive evaluation was unremarkable except for HLA-B27 positivity. He failed medical therapy and underwent radical pericardiectomy with symptom resolution. Pathology confirmed fibrous pericarditis.DiscussionThis case suggests a potential autoinflammatory role of HLA-B27 in the development of CP. Although HLA-B27 is known to drive chronic inflammation in spondyloarthropathies, and these conditions have established cardiac manifestations, its relationship to pericardial disease remains poorly defined.Take-Home MessageIn otherwise idiopathic cases of CP, isolated HLA-B27 positivity may represent a potential predisposing factor warranting further investigation. History of Presentation A 40-year-old man presented with suspected constrictive pericarditis (CP) approximately 18 months after initial symptom onset. His symptoms began in January 2020 with a persistent cough for 3 months. Initial outpatient treatment for presumed bronchitis including inhalers, antibiotics, and steroids, did not improve his symptoms.Visual SummaryTimeline of Symptom Progression, Diagnostic Evaluation, Treatment, and OutcomeCMR = cardiac magnetic resonance; CP = constrictive pericarditis; T2-STIR = T2 short tau inversion recovery; TTE = transthoracic echocardiogram. Timeline of Symptom Progression, Diagnostic Evaluation, Treatment, and Outcome CMR = cardiac magnetic resonance; CP = constrictive pericarditis; T2-STIR = T2 short tau inversion recovery; TTE = transthoracic echocardiogram. Four months after symptom onset, he developed dyspnea, bilateral lower extremity edema, abdominal distention, and persistent cough, prompting presentation to the emergency department. Chest computed tomography demonstrated bilateral pleural effusions, pericardial thickening, mild-to-moderate pericardial effusion, and prominent mediastinal lymphadenopathy, leading to hospital admission for further evaluation. Transthoracic echocardiogram (TTE) demonstrated a mild pericardial effusion without features of constriction. Pericardial biopsy revealed mild chronic pericarditis with minimal fibrosis, and supraclavicular and superior mediastinal lymph node biopsies demonstrated chronic inflammation without evidence of malignancy or infection. An extensive infectious and autoimmune workup was notable for HLA-B27 positivity, an elevated erythrocyte sedimentation rate (66 mm/h), and a low serum immunoglobulin G level (552 mg/dL). Testing for tuberculosis (TB) with interferon-gamma release assay, Epstein-Barr virus, bacterial and fungal blood cultures, Coccidioides, antinuclear antibodies, antineutrophil cytoplasmic antibodies, anticyclic citrullinated peptide antibodies, and rheumatoid factor was negative, with normal complement levels, blood urea nitrogen, and thyroid-stimulating hormone. He was diagnosed with pericarditis and discharged on colchicine 0.6 mg daily and prednisone 40 mg daily. Despite therapy, his symptoms persisted. Three months after initiating treatment, positron emission tomography excluded underlying malignancy. Repeat TTE demonstrated increased pericardial thickness, and cardiac magnetic resonance (CMR) revealed a subacute effusion, circumferential thickening, and severe near-circumferential late gadolinium enhancement of the pericardium, with evidence of constrictive physiology. Because of ongoing symptoms, furosemide 40 mg daily and indomethacin 25 mg 3 times daily were initiated. Two months later, repeat TTE and CMR demonstrated persistent constrictive findings without interval improvement. Given refractory symptoms and progressive imaging evidence of constriction, his local cardiologist recommended pericardiectomy. He subsequently presented to our center for a second opinion. Past Medical History The patient had no known past medical history. Differential Diagnosis The differential for his CP included infectious, autoimmune, neoplastic, postsurgical, traumatic, radiation, metabolic, and idiopathic etiologies. An infectious cause was unlikely given negative viral serologies and TB testing, negative bacterial and fungal blood cultures, and the absence of organisms or granulomatous inflammation on lymph node and pericardial biopsy. Malignancy was excluded by positron emission tomography and lymph node biopsies. There was no history of prior cardiac surgery, chest trauma, or radiation exposure. Metabolic causes were not supported by laboratory studies. Pericardial and lymph node biopsies demonstrated chronic inflammation without malignancy or infectious features, supporting a noninfectious inflammatory process. Given HLA-B27 positivity and exclusion of alternative etiologies, HLA-B27–associated autoinflammatory pericarditis was considered a possible contributing cause. Investigations At presentation to our clinic, the patient reported significant functional limitation with mild to moderate exertion, such as walking or biking, because of dyspnea. Physical examination demonstrated elevated jugular venous pressure and a pericardial knock. Laboratory testing was overall unremarkable, with normal erythrocyte sedimentation rate (8 mm/h) and mildly elevated C-reactive protein level (3.6 mg/dL). TTE demonstrated a normal left ventricular (LV) ejection fraction, prominent septal bounce, E-wave predominant LV filling (E/A ratio: 2.07), increased medial mitral annular e' velocity (13.4 cm/s), pericardial thickening around the apex and right ventricle, and a plethoric inferior vena cava (Figure 1). CMR demonstrated mild pericardial thickening (4 mm), septal bounce, respirophasic septal shift, conical deformity of the LV, mildly increased pericardial T2 short tau inversion recovery, and diffuse pericardial late gadolinium enhancement overall consistent with active pericardial inflammation and constrictive physiology.Figure 1Transthoracic Echocardiography Demonstrating Evidence of Constrictive Physiology(A) Interventricular septal bounce (arrows). (B) Pericardial thickening (arrows) and a pericardial effusion (asterisk). (C) Dilated plethoric inferior vena cava measuring 3.2 cm in diameter. (D) Hepatic vein expiratory flow reversal in diastole (arrows). Transthoracic Echocardiography Demonstrating Evidence of Constrictive Physiology (A) Interventricular septal bounce (arrows). (B) Pericardial thickening (arrows) and a pericardial effusion (asterisk). (C) Dilated plethoric inferior vena cava measuring 3.2 cm in diameter. (D) Hepatic vein expiratory flow reversal in diastole (arrows). Management Given persistent symptoms with imaging evidence of constrictive physiology with active pericardial inflammation, medical therapy was intensified to colchicine 0.6 mg twice daily, ibuprofen 400 mg 3 times daily, and prednisone 40 mg daily with a plan for gradual steroid taper based on symptomatic improvement and normalization of inflammatory markers. Metoprolol succinate 25 mg daily was initiated for heart rate control, furosemide 40 mg daily was initiated for volume management, and the patient was recommended to avoid high-intensity exercise. Three months after presentation, the patient developed corticosteroid-induced adverse effects, including weight gain and facial swelling, prompting initiation of a prednisone taper. Rilonacept was prescribed for continued inflammation but was denied by insurance. Despite daily diuretic use, he continued to have abdominal distention and dyspnea. Three months later, despite intensified medical therapy and ongoing diuretic use, the patient continued to experience exertional dyspnea and abdominal distention. Repeat CMR demonstrated persistent constrictive physiology with significantly improved pericardial late gadolinium enhancement. In the setting of refractory symptoms and persistent constriction, surgical management with pericardiectomy was pursued. Outcome and Follow-Up Preoperative right heart catheterization demonstrated elevated right-sided filling pressures with equalization of diastolic pressures (mean right atrial pressure: 20 mm Hg, right ventricular end-diastolic pressure: 20 mm Hg, pulmonary artery diastolic pressure: 20 mm Hg, pulmonary capillary wedge pressure mean: 20 mm Hg, LV end-diastolic pressure: 20 mm Hg) and reduced cardiac output (Fick cardiac index: 1.91 L/min/m2). The patient subsequently underwent a successful radical pericardiectomy on April 26, 2022. Histopathology of the resected pericardium demonstrated fibrosis without evidence of granulomas, neovascularization, necrosis, or malignancy. Eight months postoperatively, follow-up CMR demonstrated minimal residual pericardial enhancement without evidence of significant pericardial thickening, edema, effusion, or constrictive physiology (Figure 2). Two years postoperatively, CMR demonstrated stable findings. The patient has remained asymptomatic and off all medications since his pericardiectomy.Figure 2Comparative Cardiac Magnetic Resonance T2-STIR and LGE Before and After Pericardiectomy(A and B) Preoperative T2 short tau inversion recovery and phase-sensitive inversion recovery late gadolinium enhancement sequences demonstrating circumferential pericardial edema (red arrows, A) and severe circumferential pericardial late gadolinium enhancement (B). (C and D) Corresponding postoperative sequences demonstrating resolution of edema (C) and trace residual late gadolinium enhancement (D). Comparative Cardiac Magnetic Resonance T2-STIR and LGE Before and After Pericardiectomy (A and B) Preoperative T2 short tau inversion recovery and phase-sensitive inversion recovery late gadolinium enhancement sequences demonstrating circumferential pericardial edema (red arrows, A) and severe circumferential pericardial late gadolinium enhancement (B). (C and D) Corresponding postoperative sequences demonstrating resolution of edema (C) and trace residual late gadolinium enhancement (D). Discussion Definite pericarditis is diagnosed by pleuritic chest pain or equivalent, along with 2 or more additional criterion. Additional criteria include pericardial friction rub, electrocardiographic changes such as PR depression and widespread ST-segment elevation, elevated inflammatory markers such as C-reactive protein or erythrocyte sedimentation rate, new or worsening pericardial effusion, and imaging evidence of pericardial inflammation.1,2 Patients with persistent or inadequately controlled inflammation may develop pericardial fibrosis with impaired diastolic filling, resulting in right-sided heart failure.1 The 2025 American College of Cardiology Expert Consensus Statement2 describes a multimodal framework for diagnosing CP that integrates clinical features with TTE, CMR, and hemodynamic data rather than a single diagnostic criterion. Key features include physical examination findings such as elevated jugular venous pressure and imaging findings of respirophasic septal shift, ventricular interdependence, and elevated filling pressures with diastolic equalization. Our patient demonstrated classic features of CP on physical examination, TTE, CMR, and invasive hemodynamics. Determining the underlying etiology of pericarditis is critical because potentially reversible causes influence management and prognosis.3 TB remains the most common cause of CP in endemic regions and is still encountered in North America, whereas idiopathic etiologies predominate in nonendemic regions.1,4 Endemic fungal infections are less common but recognized causes, particularly in immunocompromised patients and endemic regions.1 Etiology also likely affects outcomes, with idiopathic cases demonstrating the most favorable prognosis and post–radiation etiologies associated with the poorest outcomes.5 Effusive CP may represent a more transient phenotype, with high rates of spontaneous resolution of constrictive features.6 In this case, extensive evaluation did not identify an infectious etiology. Viral etiologies were considered unlikely given negative viral testing, and bacterial causes were similarly unlikely given negative blood cultures and no organisms identified on tissue evaluation. Interferon-gamma release assay for TB was negative. Fungal infection was considered; however, Coccidioides serologic testing was negative, and evaluation did not identify evidence of invasive fungal disease on blood cultures, imaging, or biopsy. Evaluation showed no evidence of systemic autoimmune, malignant, metabolic, traumatic, or radiation-related causes. The only notable serologic finding was HLA-B27 positivity. HLA-B27 is a major histocompatibility complex class I molecule with a well-established association with ankylosing spondylitis and axial spondyloarthritis.7,8 Cardiac involvement in systemic inflammatory disease typically manifests in conduction system abnormalities or aortopathy, with less frequent involvement of vasculature, pericardium, myocardium, or valvular diseases.9 Our patient demonstrated neither systemic inflammatory disease nor typical HLA-B27–associated cardiac manifestations. To our knowledge, HLA-B27 positivity in the absence of systemic disease has not been associated with pericardial inflammation and fibrosis. First-line therapy for acute pericarditis includes nonsteroidal anti-inflammatory drugs and colchicine, with corticosteroids or interleukin-1 inhibitor agents reserved for refractory or recurrent disease, and pericardiectomy reserved for patients with persistent CP refractory to medical management.1,3 In our case, although inflammatory markers and imaging evidence of active pericardial inflammation improved with triple therapy, imaging features of CP persisted, and the patient remained symptomatic with limited physical activity. This pattern reflects a transition from active pericardial inflammation to fixed constrictive physiology, in which normalization of inflammatory markers may occur despite improving but persistent late gadolinium enhancement on CMR and ongoing constrictive features, a process that can take months to years to resolve.1,10 Given persistent imaging evidence of active inflammation, medical management with triple therapy was continued and surgery was deferred. Because of persistent inflammation, rilonacept was pursued to further reduce inflammation in accordance with guideline-supported therapy for recurrent pericarditis, but was not approved by insurance.10 Given the spectrum of HLA-B27–associated diseases treated with tumor necrosis factor-alpha inhibitors, these agents may have offered therapeutic benefit if initiated earlier. However, with progression to established constrictive physiology, further medical management was unlikely to provide benefit, and surgical management was ultimately pursued. This case may broaden the clinical spectrum of HLA-B27–associated pathology beyond the well-recognized conduction system abnormalities and aortopathies. Although a single case does not establish causation, it suggests a potential association between isolated HLA-B27 positivity and progressive inflammatory pericardial disease. Given the potential implications, clinicians should consider HLA-B27 as a possible contributing factor in otherwise idiopathic cases of CP. Future studies should investigate the prevalence of HLA-B27 positivity in patients with idiopathic pericarditis, particularly those who progress to constriction. If such an association is established, HLA-B27 testing may have a role in etiologic evaluation in select patients with pericardial disease. Conclusions This case describes progressive CP in a patient without an identifiable underlying etiology after extensive evaluation. Although causation cannot be established, this case raises the possibility that HLA-B27–associated immune dysregulation may contribute to chronic pericardial inflammation and fibrosis in select patients. Funding Support and Author Disclosures Dr Klein has received research funding from Kiniksa Pharmaceuticals, Ventyx, and Cardiol Therapeutics; and has served on advisory boards for Kiniksa Pharmaceuticals, Cardiol Therapeutics, Ventyx, and Zydus Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.Take-Home Message•In otherwise idiopathic cases of constrictive pericarditis, isolated HLA-B27 positivity may represent a potential predisposing factor warranting further investigation. Take-Home Message •In otherwise idiopathic cases of constrictive pericarditis, isolated HLA-B27 positivity may represent a potential predisposing factor warranting further investigation. •In otherwise idiopathic cases of constrictive pericarditis, isolated HLA-B27 positivity may represent a potential predisposing factor warranting further investigation. In otherwise idiopathic cases of constrictive pericarditis, isolated HLA-B27 positivity may represent a potential predisposing factor warranting further investigation.